New antibody–drug conjugates (ADCs) developed at Institute of Science Tokyo combine a CD4 mimic with neutralizing antibodies for enhanced suppression of human immunodeficiency virus (HIV) infection. By targeting the gp120 on the viral envelope via a two-step mechanism, the ADCs effectively block viral entry—offering seven times better efficacy than existing approaches. Overall, the findings point towards a promising new direction for HIV treatment—targeting two viral sites with a single molecule.

Post hoc analysis of a multicenter cluster-RCT (NEED; 97 ICUs, China) validated the NOFI feeding intolerance prediction model in 1,545 ICU patients started on early enteral nutrition within 48 h and fed ≥ 3 days. NOFI uses primary diagnosis, APACHE II, and AGI grade. Performance was assessed by discrimination, calibration, and clinical utility (DCA/CIC). Risk strata: > 0.85 high, 0.30–0.85 middle, < 0.30 low. High-risk patients had higher 28-day mortality.

Canine cancer patients receiving a new form of immunotherapy lived longer or shorter depending on the composition of their microbiome, the community of organisms living in their gut.